Trials / Completed
CompletedNCT00420836
Tobramycin Administered by eFlow Rapid Nebulizer: Pharmacokinetic Study
Crossover Pharmacokinetic Study of Tobramycin Administered for Inhalation by PARI eFlow® Rapid Electronic Nebulizer (no Compressor) vs. PARI LC PLUSTM Jet Nebulizer (With Compressor) in Cystic Fibrosis Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (planned)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 6 Years
- Healthy volunteers
- —
Summary
This study assesses the aerosol delivery characteristics (measured by nebulization time, serum and sputum tobramycin pharmacokinetic parameters) and safety of tobramycin administered for inhalation by PARI eFlow rapid electronic nebulizer (no compressor) vs. PARI LC PLUS Jet Nebulizer (with compressor) in subjects with cystic fibrosis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tobramycin |
Timeline
- Start date
- 2006-04-01
- First posted
- 2007-01-11
- Last updated
- 2007-01-11
Source: ClinicalTrials.gov record NCT00420836. Inclusion in this directory is not an endorsement.